In today’s session Abbott Laboratories (ABT) recorded an unusually high (1,532) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ABT decrease. With 1,532 contracts traded and 42854 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ABT161216P00039000 closed last at: $0.88 or 20.5% up. About 641,607 shares traded hands. Abbott Laboratories (NYSE:ABT) has declined 11.64% since April 27, 2016 and is downtrending. It has underperformed by 16.86% the S&P500.
Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 26. They expect $0.65 EPS, up 4.84% or $0.03 from last year’s $0.62 per share. ABT’s profit will be $956.74 million for 14.78 P/E if the $0.65 EPS becomes a reality. After $0.59 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.17% EPS growth.
Abbott Laboratories (NYSE:ABT) Ratings Coverage
Out of 16 analysts covering Abbott Laboratories (NYSE:ABT), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. $90 is the highest target while $9 is the lowest. The $48.83 average target is 27.03% above today’s ($38.44) stock price. Abbott Laboratories has been the topic of 40 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, July 14 by Jefferies. The stock has “Outperform” rating given by RBC Capital Markets on Friday, January 29. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Edward Jones on Tuesday, June 21. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Saturday, August 29 by Deutsche Bank. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Monday, December 7 by Jefferies. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, October 9. The rating was upgraded by Barclays Capital to “Overweight” on Wednesday, October 7. The stock of Abbott Laboratories (NYSE:ABT) has “Neutral” rating given on Thursday, April 28 by Piper Jaffray. The company was maintained on Tuesday, June 14 by Jefferies.
According to Zacks Investment Research, “Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.”
Insitutional Activity: The institutional sentiment decreased to 0.96 in 2016 Q2. Its down 0.09, from 1.05 in 2016Q1. The ratio is negative, as 68 funds sold all Abbott Laboratories shares owned while 488 reduced positions. 79 funds bought stakes while 507 increased positions. They now own 1.05 billion shares or 2.91% more from 1.02 billion shares in 2016Q1.
The Ontario – Canada-based Toronto Dominion Bancorp has invested 0.01% in Abbott Laboratories (NYSE:ABT). Cibc Asset Incorporated reported 146,484 shares or 0.04% of all its holdings. First Manhattan last reported 0.06% of its portfolio in the stock. Pitcairn Communication accumulated 0.09% or 17,129 shares. Berkshire Asset Mgmt Limited Com Pa has 208,154 shares for 1.24% of their US portfolio. The Tennessee-based Patten And Patten Tn has invested 0.09% in Abbott Laboratories (NYSE:ABT). Moreover, Oakbrook Invs Limited Liability Co has 0.22% invested in Abbott Laboratories (NYSE:ABT) for 100,197 shares. First Western Capital Mgmt Company, a California-based fund reported 90,304 shares. Spears Abacus Advsrs Ltd Liability owns 13,873 shares or 0.07% of their US portfolio. Stevens Mgmt Lp, a Pennsylvania-based fund reported 797,019 shares. Becker Cap Mgmt has 0.02% invested in the company for 13,335 shares. Investors Capital Advisory Services holds 0.08% or 10,106 shares in its portfolio. Carroll Financial Associate has invested 0.04% of its portfolio in Abbott Laboratories (NYSE:ABT). Moreover, Nomura has 0.05% invested in Abbott Laboratories (NYSE:ABT) for 375,964 shares. Independent Port Consultants Inc, a Florida-based fund reported 2,875 shares.
Insider Transactions: Since June 1, 2016, the stock had 4 insider purchases, and 6 insider sales for $12.04 million net activity. 815 shares were sold by Salvadori Daniel Gesua Sive, worth $33,994. Shares for $1.17 million were sold by Warmuth Michael J on Tuesday, July 26. 3,400 shares with value of $126,276 were sold by ALLEN HUBERT L on Tuesday, June 28. Watkin Jared sold $20,770 worth of stock. Another trade for 51,892 shares valued at $2.10M was made by WHITE MILES D on Thursday, November 10. $200,124 worth of Abbott Laboratories (NYSE:ABT) was bought by Blount Sally E. on Tuesday, November 1. Another trade for 565 shares valued at $22,312 was sold by YOOR BRIAN B.
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The company has a market cap of $56.58 billion. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 57.81 P/E ratio. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
ABT Company Profile
Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.
More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Barrons.com which released: “Abbott Labs CEO Doubles His Stock Holdings” on November 23, 2016, also Reuters.com with their article: “Exclusive: EU regulators seen clearing $25 billion Abbott, St Jude deal: s…” published on November 15, 2016, 247Wallst.com published: “Massive Energy and Health Care Trades Highlight Insider Buying: Abbott Labs …” on November 20, 2016. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Law360.com and their article: “Deals Rumor Mill: Snapchat, Viacom, Abbott Laboratories” published on November 15, 2016 as well as Seekingalpha.com‘s news article titled: “Abbott Laboratories Is A Long-Term Buy – Cramer’s Lightning Round (11/18/16)” with publication date: November 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.